NCT03796429 - A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

December 1, 2021

Study Completion Date

March 30, 2022

Conditions

Biliary Tract Cancer

Interventions

DRUG

GS+Toripalimab

"Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid\*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years)."

Trial Locations (1)

200032

Zhongshan Hospital Affiliated to Fudan University, Shanghai